PFE

Jim Cramer stared down a stock yielding 7% and sitting near its 52-week low, and still would not tell viewers to buy it.

Income investors watching the calendar have a narrow window this week. Three of the market's most widely held high-yield names are about to lock their next payment rosters, and the buy-by deadlines are close enough that a delayed brokerage order could push readers a full quarter down the line before the next check clears.

Pfizer (PFE) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Healthcare has been an unloved corner of the market in 2026, but that neglect has created a rare setup: quality names trading in single-digit and low-double-digit territory while still throwing off cash, growing earnings, and reaffirming guidance.

AZN targets continued 2026 growth with expanding blockbuster medicines, a strong pipeline and 2030 revenue goals as it outpaces Pfizer on key metrics.

Healthcare has become Wall Street's bargain bin in 2026, and value hunters are starting to pay attention.

Medicare's new GLP-1 coverage could expand access to weight-loss drugs, making ETFs a diversified way to tap growth across the obesity treatment market.

I keep buying Pfizer (NYSE:PFE | PFE Price Prediction) every time my brokerage cash builds up, and I am not slowing down.

Few large-cap dividends generate as much skepticism as Pfizer (NYSE:PFE | PFE Price Prediction).

This relationship between inflation and value stocks' outperformance is often overlooked. Many investment experts mistakenly believe that a strong economy, not inflation, is the key to value stocks beating growth stocks.